Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2004

View Archived Issues

Eisai investigating novel AMPA receptor antagonists

Analgesic efficacy of tetrodotoxin in refractory cancer pain

Benefits of Permixon in patients with prostatic disorders

Analysis suggesting MC-1 effective in diabetic patients with hypertension supports MC-4232 program

Human growth hormone found effective against wasting in HIV patients receiving HAART

First double-blind evidence for efficacy of topical clonazepam in stomatodynia

Dual PPARalpha/gamma agonists under investigation for metabolic syndromes at Dr. Reddy

Novel potent inhibitors of palmitoyl-CoA oxidation

Update on novel antitumor drugs under development by Salmedix

Amgen returns epratuzumab rights to Immunomedics

Approval for new formulation of Protonix I.V.

Phase III MabThera trial meets primary endpoints two years early

Acambis suspends enrollment in ACAM-2000 phase III trials

Phase I protocol for ENT-103 being drawn up

New phase II trial evaluates elsamitrucin for refractory NHL

West Nile patient responds to GenoMed treatment

Sangart cleared to commence Swedish phase II trial of Hemospan

CS-917 completes second phase IIa trial

Phase II Pentrix trial set to commence

Cytos' second Immunodrug platform enters clinical development

Gabitril to enter phase III trial in second half of 2004

Expanded Provigil label approved in U.K.

Termination of Ono and Cortech's oral elastase inhibitor agreement

mGluR2 receptor agonists for neurological, psychiatric disorders claimed by Merck

Pfizer patents MMP-12 and MMP-13 inhibitors for treatment of respiratory diseases

C5a receptor modulators in early development at Neurogen

Orchid develops novel oxazolidinone derivatives useful as antibacterial agents

New biphenyl cannabinoids described in patent literature

Novel pyridyl substituted heterocycles for treatment, prevention of HCV

Patent claims method for treatment of osteoarthritis, rheumatoid arthritis, etc.

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...